<DOC>
	<DOCNO>NCT01308632</DOCNO>
	<brief_summary>Indication : Subjects glioblastoma first relapse surgery , radiotherapy first-line temozolomide ( TMZ ) . Objectives : 1 . Phase I endpoint : - To determine maximum tolerate dose ( MTD ) CPT-11 administer day 8 22 combination fix , continuous , metronomic regimen TMZ , give 28-day cycle . 2 . Phase II endpoint : Primary endpoint : Progression-free survival 6 month . Secondary endpoint : Response rate , toxicity profile , overall survival . Complementary study : To assess effect treatment plasma concentration thrombospondin-1 ( TSP1 ) , soluble VEGF receptor 1 ( sVEGF-1 ) VEGF-A , correlation clinical outcome . - To assess correlation immunohistochemical expression PTEN MGMT proteins , clinical outcome .</brief_summary>
	<brief_title>Metronomic Temozolamide Patients With Recurrent Glioblastoma</brief_title>
	<detailed_description>Study Design : Open label , phase I - II trial . Phase I trial : TMZ administer fixed schedule follow : TMZ - 50 mg/m2/day divide three daily dos ( approx . 17 mg/m2/8 hour ) day 1-7 , 9-21 , 23-28 . - 100 mg/m2 morning single dose day 8 22 CPT-11 start dose : .100 mg/m2 day 8 22 , administer 3 6 hour TMZ . ( Level 1 ) .One cycle = 28 day . CPT-11 escalated successive cohort 3 patient follow : 115 , 130 , 145 , 160 mg/m2 . Three patient treat dose level 1 . If DLT , 3 new patient treat dose level 2 , . If 1 2 3 patient initially recruit treatment level experience DLT , 3 additional patient include level . If DLT register less 3 6 patient treated level , 3 new patient include next dose level . If 3 6 patient experience DLT , phase I trial close previous treatment level choose phase II trial . If 3 initial patient one level experience DLT , previous dose level use phase II trial . If DLT find dose level 1 , phase I trial re-started level -2 ( 70 mg/m2 ) -1 ( 85 mg/m2 ) . Definition DLT : - Absolute neutrophil count ( ANC ) &lt; 500/ μl &gt; 7 day - Platelet count &lt; 25000/ μl - A delay start new cycle &gt; 7 day allow recovery toxicity ( ANC ≥ 1500/ μl platelet count ≥ 100000/ μl - Febrile Neutropenia - Non-haematological toxicity grade 3-4 , except alopecia nausea/vomiting diarrhea without adequate prophylaxis treatment . Phase II trial : Patients receive treatment schedule dose level state phase I study . Treatment maintain progression excessive toxicity . Patient evaluation : A physical examination , blood count , basic biochemistry assessment perform within 3 week treatment study visit . Tumor recurrence progression demonstrate MRI scan perform within 3 week first treatment course every second course chemotherapy . The assessment tumor response base criterion define Macdonald et al . Study visit perform day 1 , 8 , 15 22 first second treatment course , day 8 22 thereafter , significant toxicity observe . Complementary study : The immunohistochemical expression PTEN MGMT assess paraffin section tumor tissue patient . Blood sample enzyme immunoassay TSP1 , sVEGFR-1 VEGF-A collect within 3 week treatment , course 1 every 3 treatment course thereafter .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . Patients &gt; 18 year old 2 . Histological confirm GB first relapse , assess MRI scan , surgical resection biopsy , radiotherapy , firstline chemotherapy TMZ . A TMZ treatment duration least 3 month require . Previous chemotherapy CPT11 allow . 3 . Karnofsky performance status ≥ 70 . 4 . ANC ≥ 1500/ μl , platelet count ≥ 100000/ μl , haemoglobin &gt; 10 g/dl , serum creatinine total bilirubin &lt; 1.5 time upper limit laboratory normal , transaminases &lt; 3.0 time upper limit laboratory normal . 5 . Stable descend corticosteroid dose ≥ 72 hour baseline MRI study treatment . 6 . Life expectancy great 3 month 7 . Written informed consent . 1 . Pregnancy breastfeed . 2 . Neurological impairment precludes comprehension treatment administration 3 . Vomiting condition interfere oral administration TMZ 4 . Previous concurrent malignancy , exclude basal cell carcinoma situ cervical cancer . 5 . Concurrent disease could interfere treatment 6 . Concurrent treatment enzymeinducing drug . Patients enzymeinducing anticonvulsant discontinue treatment least one week study treatment begin new antiepileptic treatment non enzymeinducing drug indicate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>glioblastoma</keyword>
	<keyword>temozolamide</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>TMZ</keyword>
	<keyword>irinotecan</keyword>
</DOC>